Last reviewed · How we verify
NCT04034992
A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life
trial in Chronic Kidney Disease in 1,052 participants. Completed in 30 June 2023.
30 June 2023
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,052 |
| Start date | 11 September 2019 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 43 locations across Italy, Japan, Sweden, United Kingdom, United States, Spain |
Conditions studied
- Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Sponsor
AstraZeneca — full company profile →
Who can join
Adults 18 to 130, any sex, with Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
DISCOVER CKD is an international observational cohort study in patients with CKD, comprising both prospective and retrospective patient cohorts. The study does not attempt to test any specific a priori hypotheses, is largely descriptive, and utilises data collected only under conditions of routine clinical care.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility.
James G, Garcia Sanchez JJ, Carrero JJ, Kumar S, et al · · 2022 · cited 27× · PMID 36090504 · DOI 10.1016/j.ekir.2022.05.033 -
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort.
Pollock C, James G, Garcia Sanchez JJ, Carrero JJ, et al · · 2022 · cited 25× · PMID 36325010 · DOI 10.1093/ckj/sfac168 -
Methods and rationale of the DISCOVER CKD global observational study.
Pecoits-Filho R, James G, Carrero JJ, Wittbrodt E, et al · · 2021 · cited 23× · PMID 34249352 · DOI 10.1093/ckj/sfab046 -
Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort.
Garcia Sanchez JJ, James G, Carrero JJ, Arnold M, et al · · 2023 · cited 20× · PMID 37069994 · DOI 10.1016/j.ekir.2023.01.037 -
Characteristics, Symptom Severity, and Experiences of Patients Reporting Chronic Kidney Disease in the PatientsLikeMe Online Health Community: Retrospective and Qualitative Study.
James G, Nyman E, Fitz-Randolph M, Niklasson A, et al · · 2020 · cited 18× · PMID 32673242 · DOI 10.2196/18548 -
Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort.
Pollock C, James G, Garcia Sanchez JJ, Arnold M, et al · · 2022 · cited 14× · PMID 35112306 · DOI 10.1007/s12325-021-02010-3 -
Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort.
Heerspink H, Nolan S, Carrero JJ, Arnold M, et al · · 2024 · cited 9× · PMID 38958839 · DOI 10.1007/s12325-024-02913-x -
Rates of adverse clinical events in patients with chronic kidney disease: analysis of electronic health records from the UK clinical practice research datalink linked to hospital data.
Little DJ, Arnold M, Hedman K, Sun P, et al · · 2023 · cited 5× · PMID 37020294 · DOI 10.1186/s12882-023-03119-z
Verify or expand the search:
- PubMed search for NCT04034992
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Disease
Currently open trials in the same condition.
- NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
- NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
- NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04034992 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 6 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04034992.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing